These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21976132)

  • 1. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
    Araujo JC; Mathew P; Armstrong AJ; Braud EL; Posadas E; Lonberg M; Gallick GE; Trudel GC; Paliwal P; Agrawal S; Logothetis CJ
    Cancer; 2012 Jan; 118(1):63-71. PubMed ID: 21976132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
    Araujo JC; Trudel GC; Saad F; Armstrong AJ; Yu EY; Bellmunt J; Wilding G; McCaffrey J; Serrano SV; Matveev VB; Efstathiou E; Oudard S; Morris MJ; Sizer B; Goebell PJ; Heidenreich A; de Bono JS; Begbie S; Hong JH; Richardet E; Gallardo E; Paliwal P; Durham S; Cheng S; Logothetis CJ
    Lancet Oncol; 2013 Dec; 14(13):1307-16. PubMed ID: 24211163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
    Spreafico A; Chi KN; Sridhar SS; Smith DC; Carducci MA; Kavsak P; Wong TS; Wang L; Ivy SP; Mukherjee SD; Kollmannsberger CK; Sukhai MA; Takebe N; Kamel-Reid S; Siu LL; Hotte SJ
    Invest New Drugs; 2014 Oct; 32(5):1005-16. PubMed ID: 24788563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
    Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
    J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
    Yu EY; Massard C; Gross ME; Carducci MA; Culine S; Hudes G; Posadas EM; Sternberg CN; Wilding G; Trudel GC; Paliwal P; Fizazi K
    Urology; 2011 May; 77(5):1166-71. PubMed ID: 21539969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Creel P; Turnbull J; Moore C; Jaffe TA; Haley S; Petros W; Yenser S; Gockerman JP; Sleep D; Hurwitz H; George DJ
    Clin Cancer Res; 2008 Oct; 14(19):6270-6. PubMed ID: 18829508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
    Yu EY; Wilding G; Posadas E; Gross M; Culine S; Massard C; Morris MJ; Hudes G; Calabrò F; Cheng S; Trudel GC; Paliwal P; Sternberg CN
    Clin Cancer Res; 2009 Dec; 15(23):7421-8. PubMed ID: 19920114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.
    Twardowski PW; Beumer JH; Chen CS; Kraft AS; Chatta GS; Mitsuhashi M; Ye W; Christner SM; Lilly MB
    Anticancer Drugs; 2013 Aug; 24(7):743-53. PubMed ID: 23652277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
    Morris MJ; Pandit-Taskar N; Carrasquillo J; Divgi CR; Slovin S; Kelly WK; Rathkopf D; Gignac GA; Solit D; Schwartz L; Stephenson RD; Hong C; Delacruz A; Curley T; Heller G; Jia X; O'Donoghue J; Larson S; Scher HI
    J Clin Oncol; 2009 May; 27(15):2436-42. PubMed ID: 19364960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
    Koreckij T; Nguyen H; Brown LG; Yu EY; Vessella RL; Corey E
    Br J Cancer; 2009 Jul; 101(2):263-8. PubMed ID: 19603032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.
    Lin J; Sinibaldi VJ; Carducci MA; Denmeade S; Song D; Deweese T; Eisenberger MA
    Urol Oncol; 2011; 29(6):670-5. PubMed ID: 19962920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer.
    Dayyani F; Varkaris A; Araujo JC; Song JH; Chatterji T; Trudel GC; Logothetis CJ; Gallick GE
    Prostate; 2013 Jun; 73(9):979-85. PubMed ID: 23371521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
    Secord AA; Teoh DK; Barry WT; Yu M; Broadwater G; Havrilesky LJ; Lee PS; Berchuck A; Lancaster J; Wenham RM
    Clin Cancer Res; 2012 Oct; 18(19):5489-98. PubMed ID: 22837181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
    Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
    George DJ; Halabi S; Healy P; Barak I; Winters C; Anand M; Wilder R; Klein M; Martinez E; Nixon AB; Harrison MR; Szmulewitz R; Armstrong AJ
    Prostate; 2019 Nov; 79(15):1752-1761. PubMed ID: 31497882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
    Quinn DI; Tangen CM; Hussain M; Lara PN; Goldkorn A; Moinpour CM; Garzotto MG; Mack PC; Carducci MA; Monk JP; Twardowski PW; Van Veldhuizen PJ; Agarwal N; Higano CS; Vogelzang NJ; Thompson IM
    Lancet Oncol; 2013 Aug; 14(9):893-900. PubMed ID: 23871417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer.
    Crabb SJ; Birtle AJ; Martin K; Downs N; Ratcliffe I; Maishman T; Ellis M; Griffiths G; Thompson S; Ksiazek L; Khoo V; Jones RJ
    Invest New Drugs; 2017 Oct; 35(5):599-607. PubMed ID: 28144789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
    Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
    Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.
    Garcia JA; Hutson TE; Shepard D; Elson P; Dreicer R
    Cancer; 2011 Feb; 117(4):752-7. PubMed ID: 20922803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.